When approaching cell and gene therapies (CGT), investors want to back companies that demonstrate operational foresight. Here are five levers for building a CGT operating model that can tackle the category’s unique commercialization complexities.The past two years have tested the cell and gene therapy (CGT) space. While Vertex’s Casgevy approval at a fraction of its […]
